Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25045626 | 0.79 | ROCK2 (0.31) | ROCK2ROCK1CDC42BPBCCR1CCR5 | |
| SCHEMBL23432271 | 0.78 | ADRA2A (0.33) | ROCK1LRRK2CDK9S1PR1S1PR3 | |
| SCHEMBL25044260 | 0.73 | KDM4E (0.35) | S1PR1S1PR3 | |
| SCHEMBL25124865 | 0.71 | LRRK2 (0.47) | ROCK2ROCK1CDC42BPBLRRK2 | |
| SCHEMBL25124487 | 0.68 | CYP2A6 (0.46) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL25124832 | 0.68 | QDPR (0.33) | CDK9 | |
| SCHEMBL24782839 | 0.67 | CDK9 (0.41) | LRRK2CDK9 | |
| SCHEMBL25124542 | 0.67 | PIK3CA (0.39) | LRRK2 | |
| SCHEMBL256752 | 0.64 | HTR2A (0.47) | CCR1CCR5CCR8 | |
| SCHEMBL15345179 | 0.64 | CCR1 (0.52) | CCR1CCR5CCR8LRRK2WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | ROCK2 7/4885ROCK1 1/4885CDC42BPB 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.